标题
Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-08-06
DOI
10.3389/fphar.2019.00872
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Utilization of the validated Psoriasis Epidemiology Screening Tool (PEST) to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry
- (2019) P. J. Mease et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis
- (2019) Vibeke Strand et al. Journal of Comparative Effectiveness Research
- Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Meta-Analysis
- (2019) Ahmed Mourad et al. JOURNAL OF RHEUMATOLOGY
- Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
- (2018) Philip Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects
- (2018) Sauzanne Khalilieh et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
- (2018) Marie-Astrid Boutet et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
- (2018) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Atul Deodhar et al. LANCET
- Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis
- (2018) Lu Yang et al. Arthritis & Rheumatology
- Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials
- (2018) Ahmed A. Suleiman et al. CLINICAL PHARMACOKINETICS
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
- (2018) Kenneth B Gordon et al. LANCET
- Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials
- (2018) Philip Mease et al. ARTHRITIS CARE & RESEARCH
- Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial
- (2018) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review
- (2018) Maxime Sondag et al. CLINICAL RHEUMATOLOGY
- Tildrakizumab for the treatment of psoriasis
- (2018) Rodney Sinclair et al. Expert Review of Clinical Immunology
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases
- (2018) Lazaros I. Sakkas et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Psoriasis pathogenesis and the development of novel targeted immune therapies
- (2017) Jason E. Hawkes et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
- (2017) Peter Nash et al. LANCET
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis
- (2017) Dongze Wu et al. RHEUMATOLOGY
- Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
- (2017) P. Kawalec et al. RHEUMATOLOGY INTERNATIONAL
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
- (2016) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
- (2016) Yanli Zhuang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a
- (2016) Ka Lun Cheung et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
- (2015) Michele W L Teng et al. NATURE MEDICINE
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
- (2014) Christopher Ritchlin et al. ANNALS OF THE RHEUMATIC DISEASES
- Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
- (2014) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- The Human IL-17F/IL-17A Heterodimeric Cytokine Signals through the IL-17RA/IL-17RC Receptor Complex
- (2014) J. F. Wright et al. JOURNAL OF IMMUNOLOGY
- Pharmacologic Inhibition of ROR t Regulates Th17 Signature Gene Expression and Suppresses Cutaneous Inflammation In Vivo
- (2014) J. Skepner et al. JOURNAL OF IMMUNOLOGY
- Psoriasis prevalence among adults in the United States
- (2014) Tara D. Rachakonda et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
- (2014) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice
- (2014) I. Khmaladze et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?
- (2014) Lisa GM van Baarsen et al. ARTHRITIS RESEARCH & THERAPY
- The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis
- (2014) Roberto Lande et al. Nature Communications
- IL-17 and TNF Synergistically Modulate Cytokine Expression while Suppressing Melanogenesis: Potential Relevance to Psoriasis
- (2013) Claire Q.F. Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics
- (2013) Philip J. Mease et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
- (2013) Iain B McInnes et al. LANCET
- The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
- (2013) Michelle A. Lowes et al. TRENDS IN IMMUNOLOGY
- Th17 and Th22 cells in psoriatic arthritis and psoriasis
- (2013) Helen Benham et al. ARTHRITIS RESEARCH & THERAPY
- IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells
- (2012) Jonathan P Sherlock et al. NATURE MEDICINE
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
- (2012) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-17C Promotes Th17 Cell Responses and Autoimmune Disease via Interleukin-17 Receptor E
- (2011) Seon Hee Chang et al. IMMUNITY
- Signaling of interleukin-17 family cytokines in immunity and inflammation
- (2010) Seon Hee Chang et al. CELLULAR SIGNALLING
- Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin
- (2009) C. Johansen et al. BRITISH JOURNAL OF DERMATOLOGY
- Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis
- (2008) Alexa B. Kimball ARCHIVES OF DERMATOLOGY
- Regulation of inflammatory responses by IL-17F
- (2008) Xuexian O. Yang et al. JOURNAL OF EXPERIMENTAL MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started